Last checked at 29 Mar 2021 11:00
29 March 2021 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, announces that it was notified on 25 March 2021 that on the same day Chris Meredith, who is a Director and PDMR, had sold 10,165 Ordinary Shares of 5p held on his behalf and 31,125 Ordinary Shares of 5p held on behalf of his PCAs in the name of Platform Securities Nominees Limited ("Nominee") at a price of 236.5p per Ordinary Share.
The Company was also informed that at the same time Individual Savings Accounts ("ISAs") held in the name of Chris Meredith purchased 11,800 Ordinary Shares of 5p, a self-invested personal pension ("SIPP") in the name of Chris Meredith purchased 2,300 Ordinary Shares of 5p, ISAs held in the name of Chris Meredith's PCAs purchased 21,590 Ordinary Shares of 5p and a self-invested personal pension ("SIPP") in the name of Chris Meredith's PCAs purchased 5,600 Ordinary Shares of 5p. All shares were purchased at a price of 236.53p per Ordinary Share.
The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and his PCAs remains unchanged. These transactions are part of normal tax planning.
The transactions are summarised below:
Director | Number of Ordinary Shares sold from Nominee | Price per Ordinary Share sold | Number of Ordinary Shares purchased by ISAs | Price paid per Ordinary Share by ISAs | Number of Ordinary Shares purchased by a SIPP | Price paid per Ordinary Share by a SIPP |
Chris Meredith | 33,390 | 236.5p | 33,390 | 236.53p | - | - |
Chris Meredith | 7,900 | 236.5p | - | - | 7,900 | 236.53p |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
a) | Position/status: Director/PDMR | ||||||
b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: Advanced Medical Solutions Group plc | ||||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
b) | Nature of the transactions: · Sale of 33,390 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 33,390 Ordinary Shares of 5p by ISAs held in the name of Chris Meredith or Chris Meredith's PCAs | ||||||
c) | Price(s) and volume(s): Sale of shares:
| ||||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 33,390 Aggregated price: 236.5p | ||||||
e) | Date of the transaction: 25/03/2021 | ||||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
a) | Position/status: Director/PDMR | ||||||
b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: Advanced Medical Solutions Group plc | ||||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
b) | Nature of the transactions: · Sale of 7,900 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 7,900 Ordinary Shares of 5p into a SIPP held in the name of Chris Meredith or Chris Meredith's PCAs | ||||||
c) | Price(s) and volume(s): Sale of shares:
| ||||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 7,900 Aggregated price: 236.5p | ||||||
e) | Date of the transaction: 25/03/2021 | ||||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Matthew Neal / Olivia Manser | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Gary Clarence / Patrick Robb |
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.